Osmotica Pharmaceutical Corp. Announces the Appointment of Samer Kaba, M.D.
Tuesday, October 6, 2015
Posted by: Angela King
MARIETTA, Ga.--(BUSINESS WIRE)--Osmotica Pharmaceutical Corp. (“Osmotica” or the “Company”) today announced the appointment of Samer Kaba, M.D. as Vice President, Head of Global Clinical Development and Medical Affairs. In his role, Dr. Kaba will serve as a key member of the senior leadership team at Osmotica Pharmaceutical, where he is responsible for leading the global clinical development strategy and execution for the company’s medical affairs programs. Praveen Tyle, Ph.D., President and CEO of Osmotica Pharmaceutical stated, “We are very pleased to have Samer (“Sam”) as part of our senior leadership team at such an exciting time as he will be instrumental in further progressing Osmotica’s recent achievements in our two lead CNS product candidates - OntinuaTM ER and OsmolexTM ER. Osmotica is quickly moving forward to completing our Phase 3 clinical trial for OsmolexTM ER and Sam’s experience in this therapeutic area will further enhance our ability to file the 505(b)2 new drug application for OsmolexTM ER in 2016” commented Dr. Tyle. “Dr. Kaba’s experience in multiple sclerosis will also be instrumental in discussions with FDA for the approval of OntinuaTM ER, which was accepted for filing by the FDA recently.”
Dr. Kaba brings a wealth of experience in the development of pharmaceutical products for neurology, analgesia, and auto-immune diseases. He has over 15 years of pharmaceutical industry experience in global clinical development programs including early and late stage development and the submission of NDAs and global marketing authorizations. Prior to joining Osmotica Pharmaceutical, Dr. Kaba was Vice President of Neurosciences at Medpace, Chief Medical Officer at Camarago Pharmaceutical Services, and Global Head of Medical Affairs and Product Development at Premier Research Group.
Prior to joining the pharmaceutical industry, Dr. Kaba held multiple academic positions at the University of Texas MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Emory University, and maintained a neurology private practice. Dr. Kaba completed his medical degree at Damascus University School of Medicine, and his neurology training at the State University of New York at Buffalo. He also completed fellowship training in Neuro-immunology (Multiple Sclerosis) at the State University of New York at Buffalo, and in Neuro-oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Kaba is board-certified by the American Board of Psychiatry and Neurology.
About Osmotica Pharmaceutical Corp
Osmotica Pharmaceutical Corp. is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The Company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the Company’s pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.
Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.
For more information on the Company, please visit Osmotica’s website at www.osmotica.com. This press release is directed to residents of the United States.
Osmotica Pharmaceutical Corp.
Ken Gayron, 770-509-4064
Chief Financial Officer
Source. BusinessWire. http://www.businesswire.com/news/home/20151006006481/en/Osmotica-Pharmaceutical-Corp.-Announces-Appointment-Samer-Kaba#.Vhavj5Ni8RQ